Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.42 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.35 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.35 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24358023 | 1.00 | KDR (0.43) | KDRCRHR1KARS1MAP3K12KDM4E | |
| SCHEMBL24358155 | 0.99 | KDR (0.44) | KDRCRHR1KARS1MAP3K12KDM4E | |
| SCHEMBL30745778 | 0.99 | KDR (0.44) | KDRCRHR1KARS1MAP3K12KDM4E | |
| SCHEMBL30745665 | 0.91 | MAP3K12 (0.42) | KDRMAP3K12SYK | |
| SCHEMBL24358235 | 0.91 | MAP3K12 (0.42) | KDRMAP3K12SYK | |
| SCHEMBL24357959 | 0.86 | MAP3K12 (0.39) | KARS1MAP3K12IDH2SYKKCNN1 | |
| SCHEMBL29601176 | 0.86 | MAP3K12 (0.39) | KARS1MAP3K12IDH2SYKKCNN1 | |
| SCHEMBL24358207 | 0.85 | TRPV1 (0.40) | MAP3K12IDH2SYK | |
| SCHEMBL30745671 | 0.85 | TRPV1 (0.40) | MAP3K12IDH2SYK | |
| SCHEMBL24358098 | 0.85 | KCNN1 (0.52) | KDRKARS1MAP3K12TRPV4KCNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2024-01-25 | — | — | US | disclosed |
| EP-4232449-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116547282-A | Heterocyclic compounds and their use for the treatment of helminth infections and diseases | 新基公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022087326-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, PAH, INHA | KDR 4128/4885CRHR1 1002/4885KARS1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.